Actinium Pharmaceuticals, Inc.

New data from Aptose Biosciences’ Phase I/II TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) show patients receiving 40mg or 80mg of the once-daily, oral multi-kinase inhibitor tuspetini

ITM Isotope Technologies Munich is preparing the complex logistics and manufacturing it will need for commercial launch of ITM-11 (non-carrier-added 177 Lu-edotreotide), its radiopharmaceutical candid

It has felt lately that there may be not be enough radiopharmaceutical companies to satisfy big pharma’s appetite. First, in December 2023, Eli Lilly and Company purchased POINT Biopharma Global In

Looking to stay ahead of the competition in the fast-moving radiopharmaceutical space, Novartis AG agreed to pay $1bn up front on 2 May to acquire privately held Mariana Oncology , a deal the pharm